Myeloma Paper of the Day, May 21st, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Clinical trial of academic BCMA CAR T HBI0101 shows 90% ORR, 56% sCR/CR, 70% MRD-negativity, median PFS 11.0 months.
High-risk CGs, EMD, and increased number of effector-memory T-cells in CAR T product associated with inferior PFS.”
Source: Robert Orlowski/X
Authors: Shlomit Kfir-Erenfeld, Nathalie Asherie, Eyal Lebel, Vladimir Vainstein, Miri Assayag, Tatyana Dubnikov Sharon, Sigal Grisariu, Batia Avni, Shlomo Elias, Rivka Alexander-Shani, Nomi Bessig, Alaa Shehadeh, Aseel Ishtay, Veronica Zelmanovich, Eran Zimran, Marjorie Pick, Ilan Roziner, Ron Kenett, Yael Cohen, Irit Avivi, Cyrille Cohen, Moshe Gatt, and Polina Stepensky.
Other insights by Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
